Clinical Decision Support Systems for Opioid Prescribing for Chronic Non-Cancer Pain in Primary Care: A Scoping Review

References

1. 1.↵
   1. Fischer B,
   2. Keates A,
   3. Bühringer G,
   4. Reimer J,
   5. Rehm J

   . Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world?. Addict Abingdon Engl 2014;109:177–81.

   OpenUrl
2. 2.↵
   Report of the International Narcotics Control Board for 2017 [Internet]. International Narcotics Control Board. 2017. Available from: https://www.incb.org/incb/en/publications/annual-reports/annual-report-2017.html.
3. 3.↵
   1. Seth P

   . Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep [Internet]. 2018 [cited 2018 Apr 23];67. Available from: https://www.cdc.gov/mmwr/volumes/67/wr/mm6712a1.htm.
4. 4.↵
   Government of Canada. National Report: Apparent opioid-related deaths in Canada [Internet]. 2018 [cited 2018 Apr 23]. Available from: www.canada.ca/en/public-health/services/publications/healthy-living/national-report-apparent-opioid-related-deaths-released-march-2018.html.
5. 5.↵
   1. Dowell D,
   2. Haegerich TM,
   3. Chou R

   . CDC Guideline for prescribing opioids for chronic pain–United States, 2016. JAMA 2016;315:1624–45.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Busse J

   . The 2017 Canadian guideline for opioids for chronic non-cancer pain [Internet]. National pain center. 2017. Available from: http://www.cmaj.ca/content/suppl/2017/05/03/189.18.E659.DC1/170363-guide-1-at-updated.pdf.
7. 7.↵
   1. Dunn KM,
   2. Saunders KW,
   3. Rutter CM,
   4. et al

   . Overdose and prescribed opioids: Associations among chronic non-cancer pain patients. Ann Intern Med 2010;152:85–92.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Bohnert AB,
   2. Valenstein M,
   3. Bair MJ,
   4. et al

   . Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011;305:1315–21.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Gomes T,
   2. Mamdani MM,
   3. Dhalla IA,
   4. Paterson JM,
   5. Juurlink DN

   . Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171:686–91.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Chou R,
    2. Turner JA,
    3. Devine EB,
    4. et al

    . The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015;162:276–86.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Volkow ND,
    2. McLellan TA,
    3. Cotto JH,
    4. Karithanom M,
    5. Weiss S

    . Characteristics of opioid prescriptions in 2009. JAMA 2011;305:1299–301.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Levy B,
    2. Paulozzi L,
    3. Mack KA,
    4. Jones CM

    . Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007–2012. Am J Prev Med 2015;49:409–13. Sep.

    OpenUrlCrossRefPubMed
13. 13.↵
    Health Quality Ontario. Starting on Opioids in Ontario [Internet]. 2017 [cited 2018 Jul 12]. Available from: http://startingonopioids.hqontario.ca/.
14. 14.↵
    1. Kawamoto K,
    2. Houlihan CA,
    3. Balas EA,
    4. Lobach DF

    . Improving clinical practice using clinical decision support systems: A systematic review of trials to identify features critical to success. BMJ 2005;330:765.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Sim I,
    2. Gorman P,
    3. Greenes RA,
    4. et al

    . Clinical Decision support systems for the practice of evidence-based medicine. J Am Med Inform Assoc JAMIA 2001;8:527–34.

    OpenUrl
16. 16.↵
    1. Haynes RB,
    2. Wilczynski NL

    . Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: Methods of a decision-maker-researcher partnership systematic review. Implement Sci IS 2010;5;5:12.

    OpenUrl
17. 17.↵
    1. Jia P,
    2. Zhang L,
    3. Chen J,
    4. Zhao P,
    5. Zhang M

    . The Effects of Clinical Decision Support Systems on Medication Safety: An Overview. PLoS One 2016;11:e0167683.

    OpenUrl
18. 18.↵
    1. Lloyd R,
    2. Ramakrishna A,
    3. Mackay JA,
    4. et al

    . Computerized clinical decision support systems for acute care management: A decision-maker-researcher partnership systematic review of effects on process of care and patient outcomes. Implement Sci IS 2011;6:91.

    OpenUrl
19. 19.↵
    1. Misra S,
    2. Gerstein HC,
    3. Garg AX,
    4. et al

    . Computerized clinical decision support systems for chronic disease management: A decision-maker-researcher partnership systematic review. Implement Sci IS 2011;6:92.

    OpenUrl
20. 20.↵
    1. Moja L,
    2. Kwag KH,
    3. Lytras T,
    4. et al

    . Effectiveness of Computerized decision support systems linked to electronic health records: A systematic review and meta-analysis. Am J Public Health 2014;104:e12–22.

    OpenUrl
21. 21.↵
    1. Jaspers MWM,
    2. Smeulers M,
    3. Vermeulen H,
    4. Peute LW

    . Effects of clinical decision-support systems on practitioner performance and patient outcomes: A synthesis of high-quality systematic review findings. J Am Med Inform Assoc 2011;18:327–34.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Nieuwlaat R,
    2. Connolly SJ,
    3. Mackay JA,
    4. et al

    . Computerized clinical decision support systems for therapeutic drug monitoring and dosing: A decision-maker-researcher partnership systematic review. Implement Sci IS 2011;6:90.

    OpenUrl
23. 23.↵
    1. Sebaldt RJ,
    2. Mackay JA,
    3. Prorok JC,
    4. et al

    . Computerized clinical decision support systems for primary preventive care: A decision-maker-researcher partnership systematic review of effects on process of care and patient outcomes. Implement Sci IS 2011;6:87.

    OpenUrl
24. 24.↵
    1. Hemens BJ,
    2. Holbrook A,
    3. Tonkin M,
    4. et al

    . Computerized clinical decision support systems for drug prescribing and management: A decision-maker-researcher partnership systematic review. Implement Sci IS 2011;6:89.

    OpenUrl
25. 25.↵
    1. Bright TJ,
    2. Wong A,
    3. Dhurjati R,
    4. et al

    . Effect of clinical decision-support systems: A systematic review. Ann Intern Med 2012;157:29–43.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Roshanov PS,
    2. Fernandes N,
    3. Wilczynski JM,
    4. et al

    . Features of effective computerised clinical decision support systems: Meta-regression of 162 randomised trials. BMJ 2013;346:f657–f657.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Garg AX,
    2. Adhikari NKJ,
    3. McDonald H,
    4. et al

    . Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: A systematic review. JAMA 2005;293:1223–38.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Holstiege J,
    2. Mathes T,
    3. Pieper D

    . Effects of computer-aided clinical decision support systems in improving antibiotic prescribing by primary care providers: A systematic review. J Am Med Inform Assoc 2015;22:236–42.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Stultz JS,
    2. Nahata MC

    . Computerized clinical decision support for medication prescribing and utilization in pediatrics. J Am Med Inform Assoc 2012;19:942–53.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Moxey A,
    2. Robertson J,
    3. Newby D,
    4. Hains I,
    5. Williamson M,
    6. Pearson SA

    . Computerized clinical decision support for prescribing: Provision does not guarantee uptake. J Am Med Inform Assoc 2010;17:25–33.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Patterson ES,
    2. Doebbeling BN,
    3. Fung CH,
    4. Militello L,
    5. Anders S,
    6. Asch SM

    . Identifying barriers to the effective use of clinical reminders: Bootstrapping multiple methods. J Biomed Inform 2005;38:189–99.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Arts DL,
    2. Medlock SK,
    3. van Weert H,
    4. Wyatt JC,
    5. Abu-Hanna A

    . Acceptance and barriers pertaining to a general practice decision support system for multiple clinical conditions: A mixed methods evaluation. PLoS ONE 2018;13:e0193187. [Internet]. 2018 Apr [cited 2018 19] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908177/.

    OpenUrl
33. 33.↵
    1. Dalleur O,
    2. Seger DL,
    3. Slight SP,
    4. et al

    . Inappropriate overrides of age-related alerts in prescriber order entry. J Gen Intern Med. 2015;S189–S190.
34. 34.↵
    1. Slight SP,
    2. Beeler PE,
    3. Seger DL,
    4. et al

    . An evaluation of drug-allergy interaction alert overrides in inpatients. J Gen Intern Med 2015;S81.
35. 35.↵
    1. Craig P,
    2. Dieppe P,
    3. Macintyre S,
    4. Michie S,
    5. Nazareth I,
    6. Petticrew M

    . Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337: a1655.

    OpenUrlFREE Full Text
36. 36.↵
    1. Craig P,
    2. Dieppe P,
    3. Macintyre S,
    4. Michie S,
    5. Nazareth I,
    6. Petticrew M

    . Developing and evaluating complex interventions: The new Medical Research Council guidance. Int J Nurs Stud 2013;50:587–92.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. Catwell L,
    2. Sheikh A

    . Evaluating eHealth interventions: The need for continuous systemic evaluation. PLoS Med 2009;6:e1000126. [Internet] Aug 18 [cited 2018 Sep 24] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719100/

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Shah A

    . Characteristics of Initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015. MMWR Morb Mortal Wkly Rep [Internet]. 2017 [cited 2020 Feb 14];66. Available from: https://www.facebook.com/CDCMMWR.
39. 39.↵
    1. Dasgupta N,
    2. Beletsky L,
    3. Ciccarone D

    . Opioid crisis: No Easy fix to its social and economic determinants. Am J Public Health 2018;108:182–6.

    OpenUrlPubMed
40. 40.↵
    1. Brooks EA,
    2. Unruh A,
    3. Lynch ME

    . Exploring the lived experience of adults using prescription opioids to manage chronic noncancer pain. Pain Res Manag J Can Pain Soc 2015;20:15–22.

    OpenUrl
41. 41.↵
    1. Anderson D,
    2. Zlateva I,
    3. Khatri K,
    4. Ciaburri N

    . Using health information technology to improve adherence to opioid prescribing guidelines in primary care. Clin J Pain 2015;31:573–9.

    OpenUrl
42. 42.↵
    1. Patel S,
    2. Carmichael JM,
    3. Taylor JM,
    4. Bounthavong M,
    5. Higgins DT

    . Evaluating the Impact of a clinical decision support tool to reduce chronic opioid dose and decrease risk classification in a veteran population. Ann Pharmacother 2018;52:325–31.

    OpenUrl
43. 43.↵
    1. Canada RE,
    2. DiRocco D,
    3. Day S

    . A better approach to opioid prescribing in primary care. J Fam Pract 2014;63:E1–E8.

    OpenUrl
44. 44.↵
    1. Gugelmann H,
    2. Shofer FS,
    3. Meisel ZF,
    4. Perrone J

    . Multidisciplinary intervention decreases the use of opioid medication discharge packs from 2 urban EDs. Am J Emerg Med 2013;31:1343–8.

    OpenUrl
45. 45.↵
    1. Sproule BA

    . Prescription Monitoring programs in canada: best practice and program review [Internet]. Canadian Centre on Substance Abuse, Ottawa, ON 2015;[cited 2018 Jun 14]. Available from: http://www.ccsa.ca/Resource%20Library/CCSA-Prescription-Monitoring-Programs-in-Canada-Report-2015-en.pdf.
46. 46.↵
    1. Rutkow L,
    2. Smith KC,
    3. Lai AY,
    4. Vernick JS,
    5. Davis CS,
    6. Alexander GC

    . Prescription drug monitoring program design and function: A qualitative analysis. Drug Alcohol Depend 2017;180:395–400.

    OpenUrl
47. 47.↵
    1. Baehren DF,
    2. Marco CA,
    3. Droz DE,
    4. Sinha S,
    5. Callan EM,
    6. Akpunonu P

    . A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med 2010;56:19–23.e1-3.

    OpenUrlCrossRefPubMed
48. 48.↵
    1. Lin HC,
    2. Wang Z,
    3. Boyd C,
    4. Simoni-Wastila L,
    5. Buu A

    . Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. Addict Behav 2018;76:348–54.

    OpenUrl
49. 49.↵
    1. Kohlbeck S,
    2. Akert B,
    3. Pace C,
    4. Zosel A

    . A multistep approach to address clinician knowledge, attitudes, and behavior around opioid prescribing. Wis Med J 2018;117:38–41.

    OpenUrl
50. 50.↵
    1. Click IA,
    2. Basden JA,
    3. Bohannon JM,
    4. Anderson H,
    5. Tudiver F

    . Opioid Prescribing in rural family practices: A qualitative study. Subst Use Misuse 2018;53:533–40.

    OpenUrl
51. 51.↵
    1. Coleman CD

    . Evidence-Based strategies to minimize risk for opioid pain medication misuse among patients with chronic pain in a primary care setting. Diss Abstr Int Sect B Sci Eng 2016;64:
52. 52.↵
    1. Chaudhary S,
    2. Compton P

    . Use of risk mitigation practices by family nurse practitioners prescribing opioids for the management of chronic nonmalignant pain. Subst Abuse 2017;38:95–104.

    OpenUrl
53. 53.↵
    1. Arksey H,
    2. O'Malley L

    . Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8:19–32.

    OpenUrlCrossRef
54. 54.↵
    1. Levac D,
    2. Colquhoun H,
    3. O'Brien KK

    . Scoping studies: Advancing the methodology. Implement Sci 2010;5:69.

    OpenUrlCrossRefPubMed
55. 55.↵
    1. Colquhoun HL,
    2. Levac D,
    3. O'Brien KK,
    4. et al

    . Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol 2014;67:1291–4.

    OpenUrlCrossRefPubMed
56. 56.↵
    1. Peters M,
    2. Godfrey C,
    3. McInerney P,
    4. Soares C,
    5. Khalil H,
    6. Parker D

    . The Joanna Briggs Institute Reviewers' Manual 2015: Methodology for JBI scoping reviews. 2015 Jan 1 [cited 2018 Feb 7]; Available from: https://espace.library.uq.edu.au/view/UQ:371443.
57. 57.↵
    1. Tricco AC,
    2. Lillie E,
    3. Zarin W,
    4. et al

    . PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med 2018;169:467. [Internet] Sep 4 [cited 2018 Sep 21]; Available from: http://annals.org/article.aspx?doi=10.7326/M18-0850.

    OpenUrlCrossRefPubMed
58. 58.↵
    1. Li G,
    2. Abbade LPF,
    3. Nwosu I,
    4. et al

    . A scoping review of comparisons between abstracts and full reports in primary biomedical research. BMC Med Res Methodol 2017;17:181.

    OpenUrl
59. 59.↵
    1. Main C,
    2. Moxham T,
    3. Wyatt JC,
    4. Kay J,
    5. Anderson R,
    6. Stein K

    . Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems [Internet]. NIHR J Library 2010; [cited 2018 Jan 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK56829/.
60. 60.↵
    Grey matters: A practical tool for searching health-related grey literature | CADTH.ca [Internet]. [cited 2018 Sep 24]. Available from: https://www.cadth.ca/resources/finding-evidence/grey-matters.
61. 61.↵
    1. Liebschutz JM,
    2. Xuan Z,
    3. Shanahan CW,
    4. et al

    . Improving adherence to long-term opioid therapy guidelines to reduce opioid misuse in primary care: A cluster-randomized clinical trial. JAMA Intern Med 2017;177:1265–72.

    OpenUrl
62. 62.↵
    1. Downes JM,
    2. Klepser DG,
    3. Foster J,
    4. Nelson M

    . Development of a standardized approach for managing opioids in adults with chronic noncancer pain. Am J Health-Syst Pharm 2018;75:321–6.

    OpenUrlAbstract/FREE Full Text
63. 63.↵
    1. Seal KH,
    2. Borsari B,
    3. Tighe J,
    4. et al

    . Optimizing pain treatment interventions (OPTI): A pilot randomized controlled trial of collaborative care to improve chronic pain management and opioid safety-rationale, methods, and lessons learned. Contemp Clin Trials 2019;77:76–85.

    OpenUrl
64. 64.↵
    1. Binswanger IA,
    2. Joseph N,
    3. Hanratty R,
    4. et al

    . Novel opioid safety clinic initiative to deliver guideline-concordant chronic opioid therapy in primary care. Mayo Clin Proc Innov Qual Outcomes 2018;2:309–16.

    OpenUrl
65. 65.↵
    1. Freeman PR,
    2. Curran GM,
    3. Drummond KL,
    4. et al

    . Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. Res Soc Adm Pharm RSAP 2019;15:754–60.

    OpenUrl
66. 66.↵
    1. Patchett D,
    2. Grover M,
    3. Kresin M,
    4. et al

    . The benefits of a standardized approach to opioid prescribing. J Fam Pract 2019;68:E1–E7.

    OpenUrl
67. 67.↵
    Prescribing and Dispensing policies to address harms associated with prescription drug abuse | CADTH.ca [Internet]. [cited 2018 Aug 20]. Available from: https://www.cadth.ca/prescribing-and-dispensing-policies-address-harms-associated-prescription-drug-abuse.
68. 68.↵
    1. McCarthy M

    . Containing the opioid overdose epidemic. BMJ 2012;345:e8340–e8340.

    OpenUrlFREE Full Text
69. 69.↵
    1. Trafton J,
    2. Martins S,
    3. Michel M,
    4. et al

    . Evaluation of the acceptability and usability of a decision support system to encourage safe and effective use of opioid therapy for chronic, noncancer pain by primary care providers. Pain Med 2010;11:575–85.

    OpenUrl
70. 70.↵
    1. Furlan AD,
    2. Reardon R,
    3. Salach L

    . The opioid manager: a point-of-care tool to facilitate the use of the Canadian Opioid Guideline. J Opioid Manag 2012;8:57–61.

    OpenUrlCrossRefPubMed
71. 71.↵
    1. Midboe AM,
    2. Lewis ET,
    3. Cronkite RC,
    4. et al

    . Behavioral medicine perspectives on the design of health information technology to improve decision-making, guideline adherence, and care coordination in chronic pain management. Behav Med Pract Policy Res 2011;1:35–44.

    OpenUrl
72. 72.↵
    1. Harle CA,
    2. Bauer SE,
    3. Hoang HQ,
    4. Cook RL,
    5. Hurley RW,
    6. Fillingim RB

    . Decision support for chronic pain care: how do primary care physicians decide when to prescribe opioids? a qualitative study. BMC Fam Pract 2015;16:48.

    OpenUrl
73. 73.↵
    1. Finley EP,
    2. Garcia A,
    3. Rosen K,
    4. McGeary D,
    5. Pugh MJ,
    6. Potter JS

    . Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res 2017;17:420.

    OpenUrl
74. 74.↵
    1. Fink DS,
    2. Schleimer JP,
    3. Sarvet A,
    4. et al

    . Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: A systematic review. Ann Intern Med 2018;168:783. Jun 5.

    OpenUrl
75. 75.↵
    Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.

    OpenUrlAbstract/FREE Full Text
76. 76.↵
    Health Quality Ontario. Recommendations for adoption: Opioid Prescribing for chronic pain [Internet]. 2018 [cited 2018 Jul 20]. Available from: http://www.hqontario.ca/Portals/0/documents/evidence/quality-standards/qs-opioid-chronic-pain-recommendations-for-adoption-en.pdf.
77. 77.↵
    1. Ciani O,
    2. Buyse M,
    3. Drummond M,
    4. Rasi G,
    5. Saad ED,
    6. Taylor RS

    . Time to review the role of surrogate end points in health policy: State of the art and the way forward. Value Health 2017;20:487–95.

    OpenUrl
78. 78.↵
    1. Wittes J,
    2. Lakatos E,
    3. Probstfield J

    . Surrogate endpoints in clinical trials: Cardiovascular diseases. Statist Med 1989;8:415–25.

    OpenUrl
79. 79.↵
    1. Gomes T,
    2. Khuu W,
    3. Martins D,
    4. et al

    . Contributions of prescribed and non-prescribed opioids to opioid related deaths: Population based cohort study in Ontario. Canada. BMJ 2018;362:k3207.

    OpenUrl
80. 80.↵
    1. Mars SG,
    2. Bourgois P,
    3. Karandinos G,
    4. Montero F,
    5. Ciccarone D

    . “Every ‘never’ I ever said came true”: Transitions from opioid pills to heroin injecting. Int J Drug Policy 2014;25:257–66.

    OpenUrlCrossRefPubMed
81. 81.↵
    1. Compton WM,
    2. Jones CM,
    3. Baldwin GT

    . Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med 2016;374:154–63.

    OpenUrlCrossRefPubMed
82. 82.↵
    1. Baldwin N,
    2. Gray R,
    3. Goel A,
    4. Wood E,
    5. Buxton JA,
    6. Rieb LM

    . Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: An observational analysis. Drug Alcohol Depend 2018;185:322–7.

    OpenUrlCrossRefPubMed
83. 83.↵
    1. Rubin R

    . Illicit fentanyl driving opioid overdose deaths. JAMA 2017;318:2174.

    OpenUrlPubMed
84. 84.↵
    1. O'Donnell J,
    2. Gladden RM,
    3. Seth P

    . Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region—United States. [Internet] 2017;2006–2015. [cited 2018 Oct 1]. Available from: https://www-cdc-gov.myaccess.library.utoronto.ca/mmwr/volumes/66/wr/mm6634a2.htm?s_cid=mm6634a2_e.
85. 85.↵
    1. Rhodes E,
    2. Wilson M,
    3. Robinson A,
    4. Hayden JA,
    5. Asbridge M

    . The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: A systematic review. BMC Health Serv Res 2019;19:784.

    OpenUrl
86. 86.↵
    1. Heres S,
    2. Davis J,
    3. Maino K,
    4. Jetzinger E,
    5. Kissling W,
    6. Leucht S

    . Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. AJP 2006;163:185–94.

    OpenUrl
87. 87.↵
    1. Lexchin J,
    2. Bero LA,
    3. Djulbegovic B,
    4. Clark O

    . Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 2003;326:1167–1170.

    OpenUrlAbstract/FREE Full Text
88. 88.↵
    1. Lesser LI,
    2. Ebbeling CB,
    3. Goozner M,
    4. Wypij D,
    5. Ludwig DS

    . Relationship between funding source and conclusion among nutrition-related scientific articles. PLoS Med 2007;4:e5.

    OpenUrlCrossRefPubMed
89. 89.↵
    1. Procyshyn RM,
    2. Chau A,
    3. Fortin P,
    4. Jenkins W

    . Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Can J Psychiatry 2004;49:601–6.

    OpenUrlCrossRefPubMed
90. 90.↵
    1. Turner EH,
    2. Matthews AM,
    3. Linardatos E,
    4. Tell RA,
    5. Rosenthal R

    . Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252–60.

    OpenUrlCrossRefPubMedWeb of Science
91. 91.↵
    1. Doshi P,
    2. Dickersin K,
    3. Healy D,
    4. Vedula SS,
    5. Jefferson T

    . Restoring invisible and abandoned trials: A call for people to publish the findings. BMJ 2013;346:f2865–f2865.

    OpenUrlFREE Full Text
92. 92.↵
    1. Chan AW,
    2. Hróbjartsson A,
    3. Haahr MT,
    4. Gøtzsche PC,
    5. Altman DG

    . Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA 2004;291:2457–65.

    OpenUrlCrossRefPubMedWeb of Science
93. 93.↵
    Electronic health records vendor to pay $145 million to resolve criminal and civil investigations [Internet]. 2020 [cited 2020 Feb 14]. Available from: https://www.justice.gov/opa/pr/electronic-health-records-vendor-pay-145-million-resolve-criminal-and-civil-investigations-0.
94. 94.↵
    1. Mair FS,
    2. May C,
    3. O'Donnell C,
    4. Finch T,
    5. Sullivan F,
    6. Murray E

    . Factors that promote or inhibit the implementation of e-health systems: an explanatory systematic review. Bull World Health Organ 2012;90:357–64.

    OpenUrlCrossRefPubMedWeb of Science
95. 95.↵
    1. Black AD,
    2. Car J,
    3. Pagliari C,
    4. et al

    . The impact of eHealth on the quality and safety of health care: A systematic overview. PLoS Med 2011;8:e1000387. [Internet] Jan 18 [cited Jul 18] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022523/.

    OpenUrlCrossRefPubMed
96. 96.↵
    National Center for Injury Prevention and Control. Integrating & Expanding Prescription Drug Monitoring Program Data: Lessons from Nine States. Centre for Disease Control and Prevention 2017.
97. 97.↵
    1. Moore GF,
    2. Audrey S,
    3. Barker M,
    4. et al

    . Process evaluations of complex interventions: UK Medical Research Council (MRC) guidance [Internet]. MRC Population Health Science Research Network 2014;[cited 2018 Jul 23]. Available from: https://mrc.ukri.org/documents/pdf/mrc-phsrn-process-evaluation-guidance-final/
98. 98.↵
    1. Chan CL,
    2. Leyrat C,
    3. Eldridge SM

    . Quality of reporting of pilot and feasibility cluster randomised trials: A systematic review. BMJ Open 2017;7:e016970.

    OpenUrl
99. 99.↵
    1. Liu H,
    2. Muhunthan J,
    3. Hayek A,
    4. et al

    . Examining the use of process evaluations of randomised controlled trials of complex interventions addressing chronic disease in primary health care—A systematic review protocol. Syst Rev 2016;5. [cited 2018 Sep 24] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986376/.
100. 100.↵
     1. Oakley A,
     2. Strange V,
     3. Bonell C,
     4. Allen E,
     5. Stephenson J

     . Process evaluation in randomised controlled trials of complex interventions. BMJ 2006;332:413–6.

     OpenUrlFREE Full Text
101. 101.↵
     1. Greenhalgh T,
     2. Russell J

     . Why do evaluations of eHealth programs fail? An alternative set of guiding principles. PLoS Med 2010;7:e1000360. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2970573/.

     OpenUrlCrossRefPubMed
102. 102.↵
     1. Basit MA,
     2. Baldwin KL,
     3. Kannan V,
     4. et al

     . Agile acceptance test–driven development of clinical decision support advisories: feasibility of using open source software. JMIR Med Inform 2018;6:e23. [Internet] Apr 13 [cited 2019 May] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924365/.

     OpenUrl
103. 103.↵
     1. Kannry J,
     2. McCullagh L,
     3. Kushniruk A,
     4. Mann D,
     5. Edonyabo D,
     6. McGinn T

     . A Framework for Usable and Effective Clinical Decision Support: Experience from the iCPR Randomized Clinical Trial. eGEMs 2015;3:10.

     OpenUrl
104. 104.↵
     1. Kannan V,
     2. Fish J,
     3. Mutz J,
     4. et al

     . Rapid Development of specialty population registries and quality measures from electronic health record data: An agile framework. Methods Inf Med 2017;56:e74–83.

     OpenUrl